Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
TCT 25: Short-Term Anticoagulation Vs DAPT for Preventing Device Thrombosis Following LAAC
Author(s): Josep Rodés-Cabau Added: 2 weeks ago
TCT 2025 - Short-term anticoagulation reduced adverse events following left atrial appendage closure (LAAC) compared to dual antiplatelet therapy (DAPT).Dr Josep Rodés-Cabau (Quebec Heart and Lung Institute, Quebec, CA) joins us at TCT 2025 to discuss findings from ANDES trial (NCT03568890) investigating the safety and efficacy of short-term anticoagulation versus DAPT for preventing device… View more

Anticoagulation

Imaging & Diagnostics
Prevention: What's New at HFA 2025?
Author(s): Harriette Van Spall , Maja Cikes Added: 5 months ago
ESC HF 25 - Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Maja Cikes (University Hospital Centre Zagreb, HR) for an insightful wrap up of the novel data concerning preventive cardiology that was presented at 2025's Heart Failure Congress.Trials discussed include:REDICAE (00:42)FINEARTS HF (02:27)CRISPR Gene Editing with Nexiguran Ziclumeran (05:53)HELIOS B (07:12)RESHAPE… View more

Heart Failure
Selecting NOAC to Optimise Stroke Prevention in AF – Part 1
Author(s): Tri Huynh Quang Ho , Minh That Ton , Viet Lan Nguyen , et al Added: 1 year ago

Anticoagulation

Electrophysiology & Arrhythmia
AHA 23: Preventive Cardiology in 2023
Author(s): Michael Honigberg Added: 1 year ago
AHA 23 — Dr Michael Honigberg (Massachusetts General Hospital, US) highlights key 2023 cardiology updates, featuring novel data from AHA Scientific Sessions.Dr Honigberg provides commentary on the new SELECT trial outcomes and emphasises the incretin mimetic, semaglutide's role in cardiovascular medicine. He delves into lipid management with a focus on the CLEAR trial data and the incorporation… View more

Guidelines & Statements

Prevention & Chronic Conditions
Selecting NOAC to Optimise Stroke Prevention in AF – Part 2
Author(s): Minh That Ton , Tri Huynh Quang Ho , Viet Lan Nguyen , et al Added: 1 year ago

Anticoagulation

Electrophysiology & Arrhythmia
ESC 24: STEEER-AF: Stroke Prevention & Rhythm Control Therapy
Author(s): Dipak Kotecha Added: 1 year ago
ESC Congress 2024 — Improved patient-level adherence to guideline recommendations on heart rhythm control through healthcare professional education in patients with atrial fibrillation.Investigator, Dr Dipak Kotecha (University of Birmingham, UK) joins us in London to share key findings from the STEEER-AF study (NCT04396418).This prospective, cluster-randomized international study compared two… View more

Electrophysiology & Arrhythmia

Prevention & Chronic Conditions
ESC Preventive Cardiology 2025
Start date: Apr 03, 2025 End date: Apr 05, 2025
Dates: April 3-5, 2025Location: Milan, ItalyTheme: "Risk Factor Realities in 2025"ESC Preventive Cardiology 2025 is the premier annual congress of the European Association of Preventive Cardiology (EAPC), bringing together the leading community of healthcare professionals dedicated to cardiovascular disease prevention.The 2025 Milan congress offers an unparalleled opportunity to engage with the… View more
ESC 25: The HI-PRO Trial
Author(s): Gregory Piazza Added: 2 months ago
ESC Congress 2025 - HI-PRO shows apixaban 2.5mg twice daily reduced the risk of symptomatic recurrent venous thromboembolism when compared to placebo at 12 months.Dr Gregory Piazza (Brigham and Women's Hospital, US) joins us to discuss findings from the HI-PRO trial, evaluating extended-duration low-intensity apixaban versus placebo for secondary prevention in high-risk patients with provoked… View more

Anticoagulation

Vascular Disease and Surgery
Author(s): Manav Sohal Added: 1 year ago

Anticoagulation

Electrophysiology & Arrhythmia
ACC.24: Preventing Chemotherapy-Related Heart Damage in Patients with Breast Cancer and Lymphoma: PROACT
Author(s): David Austin Added: 1 year ago
ACC.24 — We are joined onsite by Dr David Austin (South Tees Hospitals NHS Foundation Trust, UK) to discuss the findings from the PROACT trial (NCT03265574).Anthracyclines used in the treatment of breast cancer cause damage to the muscle cells in the heart, resulting in cardiotoxicity.PROACT is a phase III randomised superiority trial of enalapril for the prevention of anthracycline-induced… View more

CV Disease in Special Populations